Lv2
178 积分 2022-03-14 加入
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
14小时前
已完结
Clinical endpoints in myositis: challenges and ways forward
10天前
已完结
The 2024 APLAR Consensus on the Management of Lupus Nephritis
3个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
3个月前
已完结
IgA nephropathy
3个月前
已完结
Shifting the SLE management paradigm: challenges and implications
4个月前
已完结
The global burden of SLE: prevalence, health disparities and socioeconomic impact
4个月前
已完结
The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation
4个月前
已完结
Update on the pathophysiology and treatment of primary Sjögren syndrome
4个月前
已完结
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
4个月前
已完结
皖公网安备34019202002308
